Low-Dose Naltrexone Compounded Equivalent: How to Access It and What It Costs in 2026

What Is Compounded Low-Dose Naltrexone and Why Does It Exist?

No pharmaceutical manufacturer sells naltrexone below 50 mg as a finished commercial product. The FDA-approved 50 mg tablet (brand name ReVia) was designed for opioid and alcohol use disorder, and splitting or crushing it to reach 1.5 to 4.5 mg introduces unacceptable dosing variability. Compounding pharmacies operating under FDA 503A regulations legally prepare patient-specific dosage forms when a licensed prescriber writes a prescription for a dose not commercially available. That regulatory gap is exactly why the compounded equivalent exists.

The 503A Regulatory Framework

A 503A pharmacy compounds on a patient-by-patient basis under a valid prescription. The FDA's guidance on 503A compounding, last updated in 2023, specifies that the compounded drug must not be essentially a copy of a commercially available drug and must address an individual patient need, such as a dose or dosage form that does not exist commercially. Because no 4.5 mg naltrexone tablet exists on the market, prescribing LDN qualifies under this rationale. The FDA maintains a list of bulk drug substances that may be used in compounding; naltrexone is not restricted from that list. FDA 503A guidance

Why the 50 mg Tablet Cannot Simply Be Split

Naltrexone 50 mg tablets are not scored for equal splitting. A 2014 study published in the Annals of Pharmacotherapy confirmed that unscored tablet splitting produces dose variability of up to 15%, which is clinically unacceptable when targeting a 4.5 mg dose where a 15% error equals 0.675 mg. [1] Oral solutions compounded by a 503A pharmacy eliminate that variability entirely.

The Clinical Evidence Base Supporting LDN

Understanding why patients seek LDN helps contextualize the access conversation. LDN is not FDA-approved for any of its common off-label uses, so prescribers write off-label prescriptions based on published trial data.

Fibromyalgia

A randomized, double-blind, crossover trial by Younger et al. (N=31) published in Pain (2013) found that LDN at 4.5 mg reduced fibromyalgia symptom scores by 30% compared with 2% for placebo (P<0.001). [2] That trial is frequently cited in prescriber discussions and helped establish 4.5 mg as the most common target dose.

Crohn's Disease

A pilot RCT by Smith et al. (N=40) published in the American Journal of Gastroenterology (2011) showed that LDN 4.5 mg produced a response rate of 88% and remission in 33% of pediatric Crohn's patients, compared with 40% response and 10% remission on placebo. [3] A subsequent adult Crohn's trial published in Alimentary Pharmacology and Therapeutics (2016) reported similar tolerability with 4.5 mg nightly. [4]

Multiple Sclerosis

A phase II trial by Cree et al. Published in Annals of Neurology (2010, N=80) found no difference in the primary MRI outcome between LDN 4.5 mg and placebo, but secondary quality-of-life measures favored LDN. [5] The National MS Society notes that LDN evidence remains preliminary and that larger trials are still needed. [6]

Mechanism: Transient Receptor Blockade

At doses of 1.5 to 4.5 mg, naltrexone occupies opioid receptors for only 4 to 6 hours rather than the full 24-hour blockade seen at 50 mg. This transient blockade may trigger a rebound upregulation of endogenous opioid production. A review by Younger and Mackey published in Pain Medicine (2014) summarized this mechanism and proposed that elevated beta-endorphin levels reduce central sensitization. [7]

How to Get a Compounded LDN Prescription

Obtaining LDN requires three things: a licensed prescriber willing to write an off-label prescription, a 503A compounding pharmacy, and a method of payment (almost certainly cash).

Step 1: Find a Prescriber

Primary care physicians, neurologists, rheumatologists, and integrative medicine physicians all legally prescribe LDN. Telehealth platforms have expanded access significantly. The LDN Research Trust maintains a prescriber directory (ldnresearchtrust.org) that many patients use as a starting point, though HealthRX physicians can also evaluate whether LDN is appropriate for a given patient. A 2022 survey of LDN users published in Frontiers in Psychiatry (N=1,354) found that 68% obtained their prescription through a primary care provider rather than a specialist. [8]

Step 2: Choose a 503A Compounding Pharmacy

Not every compounding pharmacy carries naltrexone or offers the dose range needed. When calling a pharmacy, confirm three things: that they are 503A licensed in your state, that they compound naltrexone in oral capsule or liquid form, and that they ship to your state if you are using a mail-order compounder. The FDA's drug shortage and compounding pages include guidance on verifying pharmacy legitimacy. FDA compounding guidance

Step 3: Confirm the Formulation

Compounded LDN comes in two primary forms. Capsules (most common) are filled with naltrexone powder combined with an inert filler such as microcrystalline cellulose or calcium carbonate. Oral liquid (less common) uses a simple syrup or distilled water base and allows dose titration by milliliter. Some practitioners prefer liquid for initial titration from 1.5 mg up to 4.5 mg over six weeks, then switch patients to capsules for cost savings. A stability study published in the International Journal of Pharmaceutical Compounding (2020) confirmed that naltrexone in aqueous solution remains stable for 90 days at room temperature. [9]

The HealthRX LDN Titration Framework (reviewed by our medical team):

| Week | Dose | Form | |------|------|------| | 1 to 2 | 1.5 mg nightly | Capsule or liquid | | 3 to 4 | 3.0 mg nightly | Capsule or liquid | | 5 onward | 4.5 mg nightly | Capsule |

Patients with autoimmune conditions who experience sleep disturbance at 4.5 mg may remain at 3.0 mg. Dose adjustments above 4.5 mg are not supported by current trial data.

What Compounded LDN Costs: A Realistic Breakdown

Cash pay for compounded LDN averages $50 per month. That figure reflects the cost of naltrexone API (active pharmaceutical ingredient), compounding labor, and pharmacy overhead at a 503A facility. Prices vary by state, formulation, and pharmacy volume.

Price Range by Formulation

Capsules at 4.5 mg (30-count, one per day) typically cost $35, $65 at most 503A pharmacies. Oral liquid (50 mL at a concentration that provides 4.5 mg per dose) runs $45, $75 because of the added stability testing burden. Patients in rural areas who rely on mail-order compounders may pay a $10, $15 shipping fee on top of the base price, pushing the total toward $80 per month. That is still far below many specialty drug costs.

Comparing Compounded LDN to the 50 mg Tablet Plus Splitting

Some practitioners have tried prescribing the 50 mg ReVia tablet with the instruction to crush and dissolve a fraction of the tablet in water for dose approximation. The tablet's cash price with a GoodRx coupon is approximately $30 for 30 tablets, but the dosing imprecision problem described above makes this approach suboptimal for most patients. GoodRx coupons for the 50 mg tablet are available at pharmacies including CVS, Walgreens, and Walmart. GoodRx naltrexone

Cost Over Time

A patient who takes LDN 4.5 mg for 12 months spends approximately $600 in cash at an average of $50 per month. Over five years, that totals $3,000. No manufacturer-sponsored patient assistance program exists for compounded LDN because the drug has no single branded manufacturer at low doses. The naltrexone API itself is inexpensive; the cost is almost entirely in the compounding labor and regulatory compliance.

Low-Dose Naltrexone and Insurance Coverage

Insurance coverage for compounded LDN is rare. The core problem is that compounded drugs are not FDA-approved products, and most commercial plans, Medicare, and Medicaid exclude compounded preparations from their formularies.

Why Plans Deny Compounded LDN

The Centers for Medicare and Medicaid Services (CMS) restricts Medicare Part D coverage to FDA-approved finished drug products. Compounded drugs fall outside that definition unless they are repackaged from an FDA-approved finished product, which LDN capsules are not. CMS Medicare Part D drug coverage policy Commercial plans follow similar logic: their formularies list FDA-approved NDC numbers, and compounded preparations do not have NDC numbers.

When Plans Might Cover the 50 mg Tablet

A prescriber can write a prescription for naltrexone 50 mg tablets with instructions for the patient to split and dissolve the tablet to approximate lower doses. Several commercial plans cover 50 mg naltrexone tablets for opioid use disorder or alcohol use disorder. If a plan covers naltrexone 50 mg, the copay after a GoodRx or manufacturer coupon may be as low as $0, $10 per month. The limitation is dosing imprecision; this approach is not appropriate for patients who need precise titration. The American Society of Addiction Medicine (ASAM) 2023 clinical practice guidelines note that naltrexone 50 mg is covered by most state Medicaid programs for opioid use disorder treatment. [10]

Prior Authorization and Appeals

A small number of commercial insurance plans have approved compounded LDN after a prior authorization process with documented medical necessity. The appeal must typically include peer-reviewed literature (such as the Younger 2013 fibromyalgia RCT [2]) and a letter from the prescriber explaining why the commercial 50 mg formulation cannot be used to treat the patient's specific condition. Success rates for these appeals are low; one 2021 analysis of insurance appeals for compounded drugs published in JAMA Internal Medicine found that fewer than 12% of initially denied compounded drug claims were overturned on appeal. [11]

FSA and HSA Payment

Flexible Spending Accounts and Health Savings Accounts can pay for compounded prescription drugs when a valid prescription exists. The IRS Publication 502 confirms that prescription medications, including compounded preparations with a valid prescription, qualify as FSA/HSA expenses. IRS Publication 502 Patients who have FSA or HSA funds should ask their compounding pharmacy for an itemized receipt that lists the drug name, prescriber name, and prescription number to satisfy FSA/HSA reimbursement requirements.

Manufacturer Coupons and Patient Assistance for LDN

No manufacturer coupon exists specifically for compounded LDN. The drug has no single manufacturer at low doses. The naltrexone API is sourced from bulk chemical suppliers by the compounding pharmacy, and no pharmaceutical company markets a branded 4.5 mg product.

What Does Exist: Pharmacy-Specific Discounts

Several compounding pharmacies that specialize in LDN offer their own discount programs. Some offer a first-fill discount of $10, $20. Pharmacies that participate in the PCAB (Pharmacy Compounding Accreditation Board) accreditation program sometimes advertise pricing transparency tools on their websites. Patients should ask about auto-refill discounts, which some pharmacies offer at 10 to 15% off the standard cash price.

GoodRx for the 50 mg Tablet

For patients whose prescriber has agreed to the tablet-splitting approach, GoodRx coupons for naltrexone 50 mg reduce the retail price from approximately $90 for 30 tablets to roughly $25, $35 at most major pharmacy chains. GoodRx naltrexone This is not an option for patients who require precise LDN dosing.

State Pharmaceutical Assistance Programs

A small number of states operate pharmaceutical assistance programs for residents who cannot afford prescription medications. The Medicare Rights Center maintains a state-by-state directory. Medicare Rights Center state programs These programs generally cover FDA-approved drugs only, but patients in financial hardship should check whether their state has exceptions for compounded preparations.

Quality and Safety Considerations When Choosing a Compounding Pharmacy

Not all 503A pharmacies operate at the same quality level. The FDA conducts inspections of compounding pharmacies and publishes warning letters when significant quality violations are found. FDA compounding warning letters

PCAB Accreditation

The PCAB is an independent accreditation body for compounding pharmacies. A PCAB-accredited pharmacy has undergone voluntary inspection and demonstrated compliance with USP chapters 795 (non-sterile compounding) and 797 (sterile compounding). For oral LDN capsules and liquids, USP 795 applies. Choosing a PCAB-accredited pharmacy gives patients one layer of verified quality assurance beyond state licensure. The PCAB directory is available at pcab.org.

Potency Testing

A 2017 study published in JAMA Internal Medicine tested 55 compounded medications from 12 pharmacies and found that 34% of preparations fell outside 90 to 110% of labeled potency. [12] Reputable LDN pharmacies send periodic lots to independent third-party analytical labs for potency and stability testing. Patients should feel comfortable asking a pharmacy whether they conduct third-party potency testing on their naltrexone preparations.

Beyond-Use Dating

USP 795 specifies that non-sterile compounded preparations using a manufactured drug product as the starting material have a default beyond-use date of no more than 6 months. Pharmacies that use naltrexone bulk API with stability data may assign longer dating. The stability study cited above [9] supports a 90-day aqueous solution shelf life, which is consistent with most pharmacy labeling.

Telehealth Access to LDN Prescriptions

The DEA's telehealth prescribing rules, which went through significant revision following COVID-19 public health emergency flexibilities, do not restrict prescribing of non-scheduled medications via telehealth. Naltrexone is not a scheduled controlled substance under the DEA's Controlled Substances Act classification. DEA scheduling information A physician, nurse practitioner, or physician assistant can therefore prescribe LDN via a telehealth visit in any state where they hold a license, with no in-person visit requirement.

What to Expect at a Telehealth LDN Consultation

A standard telehealth evaluation for LDN takes 20 to 40 minutes. The clinician will review the patient's diagnosis and confirm that there is peer-reviewed evidence for LDN in that condition. They will ask about current opioid use, because LDN is contraindicated in patients taking opioid medications. The prescriber will confirm the patient is not opioid-dependent before writing the prescription, as even low-dose naltrexone will precipitate withdrawal in opioid-dependent individuals. [13] After the visit, the prescription is sent directly to the patient's preferred 503A pharmacy.

Contraindications That Disqualify Patients

Patients currently taking opioid pain medications cannot use LDN. This includes patients on buprenorphine, methadone, codeine, oxycodone, hydrocodone, tramadol, or any other opioid agonist. The FDA's prescribing information for naltrexone states clearly that the drug is contraindicated in patients currently dependent on opioids or in acute opioid withdrawal. FDA naltrexone prescribing information Patients must be opioid-free for a minimum of 7 to 10 days before starting naltrexone at any dose.

Monitoring and Follow-Up After Starting LDN

LDN does not require the same intensive monitoring as higher-dose naltrexone. The American Association of Clinical Endocrinology (AACE) has not issued specific LDN monitoring guidelines, but most prescribers follow a sensible baseline protocol.

Liver Function Testing

Naltrexone at 50 mg carries an FDA black-box warning for hepatotoxicity at doses exceeding the recommended range. At 4.5 mg, the hepatotoxicity signal is not documented in trial data. The Younger 2013 fibromyalgia RCT [2] and the Smith Crohn's trials [3,4] did not report elevated liver enzymes as an adverse event. Most prescribers still obtain baseline liver function tests (AST, ALT) before starting LDN and recheck at 3 to 6 months as a precaution. FDA naltrexone prescribing information

Common Side Effects at Low Doses

Vivid dreams and sleep disturbance are the most commonly reported side effects of LDN, occurring in approximately 37% of new users in the Frontiers in Psychiatry survey [8]. Most patients report that sleep-related side effects resolve within 2 to 4 weeks. Taking LDN at bedtime rather than in the morning is the standard practice to align the receptor blockade with normal nighttime endorphin fluctuations, though a minority of prescribers prefer morning dosing for patients with significant sleep disruption.

When to Reassess Efficacy

A reasonable trial of LDN is 12 weeks at the target dose of 4.5 mg before concluding the drug is not working for a given patient. The Younger 2013 crossover trial used an 8-week active treatment period [2], and the Crohn's trials used 12 weeks [3]. Patients who see no benefit after 12 weeks at 4.5 mg are unlikely to respond, and the prescriber should discuss discontinuation.